AUTHORS
Jae H Park, MD, Mark Blaine Geyer, MD2, Yannis K. Valtis I, MD3, Elizabeth Miranda4, Elizabeth Cathcart5, Tyler Gunningsmith6, Xiuyan Wang7, Kevin Curran, MD8, Renier Brentjens, MD, PhD9
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
ABSTRACT
Introduction
CD19 CAR T cell therapy induces high remission rates in relapsed/refractory (R/R) B-acute lymphoblastic leukemia (ALL), yet durable remissions remain limited. Current CAR-T approaches also require lymphodepleting chemotherapy (LDC), which contributes to prolonged cytopenias, infections, and chemo-related morbidity. IL18 secreting armored CD19 CAR T cells (19-28z/IL18) were developed to enhance CAR T cell expansion, cytotoxicity, and endogenous immune activation. In our preclinical B-ALL models, 19-28z/IL18 CAR T cells demonstrated superior anti-leukemic activity without LDC, whereas conventional CAR T cells failed to achieve T-cell expansion in the absence of LDC (Avanzi M et al. Cell Rep 2018). Although LDC has been incorporated into virtually all clinical CD19 CAR T studies, its necessity for next-generation armored CAR T platforms has not been prospectively evaluated. Here, we report the initial clinical outcomes of the first prospective clinical evaluation of LDC-free 19-28z/IL18 CAR T cells in patients (pts) with R/R B-ALL (NCT06287528).
Methods
Eligible pts included pts ≥17 years old with R/R B-ALL. Prior CD19-directed therapies were allowed. The study has 2 dose levels of 0.5x106 (starting dose) and 0.1x106 CAR T cells/kg (step-down dose). All pts received a single infusion of CAR T cells without LDC. The primary objectives were to evaluate safety and determine recommended phase 2 dose of CAR T cells. Secondary objectives were to assess response rates, progress-free survival and persistence of CAR T cells. Measurable residual disease (MRD) was assessed by multiparameter flow cytometry or ClonoSEQ with a minimum 10-4 sensitivity.
Results
Six pts have been treated on study. The median age was 29 yrs old (ranges, 21-31). Three had Philadelphia chromosome-like ALL, 4 had prior allogeneic SCT, and 3 had prior CD19 CAR T cell therapy. The median bone marrow blast at treatment was 30% (0.1-99%). CAR T cells were successfully manufactured in all pts.
Five pts were treated at the starting dose (0.5x106 CAR T cells/kg). Two pts experienced a transient grade 3 ICANS that lasted <72 hours that met the dose-limiting toxicity (DLT) criteria, and 3 pts experienced grade 2 CRS that resolved <48 hours. Due to the DLT events in the first 5 pts, the next pt (pt 6) was treated at 0.1x106 CAR T cells/kg and enrollment to that cohort is currently ongoing.
Among the 6 pts treated to date (5 pts at 0.5x106 and 1 pt at 0.1x106 CAR T cells/kg), 2 pts did not respond, one of whom died of sepsis with active disease. Four pts (67%) achieved MRD negative complete remission (CR), including the last pt treated at the lowest dose level of 0.1x106 CAR T cells/kg, a pt with heterogenous CD19 expression, and 2 pts who had prior brexucabtagene and tisagenlecleucel. Two of four pts who achieved CR proceeded to allogeneic SCT. At a median follow-up of 4.4 months (range, 0.5-24), 2 pts experienced disease relapse, both CD19+. One pt relapsed one year following post-CAR allogeneic SCT and is alive following subsequent treatment including another CD19 CAR T cell therapy; the other pt relapsed with MRD+ disease at month 3 following 19-28z/IL18 and received blinatumomab, regained MRD negative CR and remains alive.
Notably, robust CAR T cell expansion was observed in all 4 responders, despite not receiving LDC. The median peak CAR T cell value was 1,131,546 vector copy number (VCN)/ml (ranges, 453,799 – 49,628,297), and the highest expansion occurred in the pt treated at the lowest dose level of 0.1x106 CAR T cells/kg. This degree of CAR T cell expansion observed without LDC is comparable to the values observed in our prior study of 19-28z CAR (same construct as the study product without IL18) in R/R ALL administered with LDC at a higher dose of 1x106 T cells/kg, where the median peak CAR T cell value was 23,082 VCN/ml (range, 268 – 29,892,388). Detailed cytokine profiling and endogenous immune activation analysis are ongoing.
Conclusions
Herein we show for the first time that even at low doses, IL18 armored CAR T cells can achieve MRD negative remissions with robust CAR T cell expansion in the absence of LDC in a meaningful cohort of pts. These findings support the hypothesis that enhanced CAR T cell biology can substitute for pharmacologic lymphodepletion, provide the first clinical validation of an LDC-free CAR T approach, and establish a foundation for further investigation of next-generation IL18 armored CAR T cells.
DISCLOSURES
Jae H Park, MD: OncLive - Honoraria; Physician Education Resource - Honoraria; MJH Life Sciences - Honoraria; Autolus - Research Funding; InCyte - Research Funding; Servier - Research Funding; Genentech - Research Funding; Fate Therapeutics - Research Funding; Autolus - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Allogene Therapeutics - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Curocell - Consultancy (Includes expert testimony); Artiva Biotherapeutics - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Caribou Biosicences - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Bright Pharmaceutical Services INC. - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Affyimmune Therapeutics - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)